Search

everythinglearnresearchcommunity

for

Search:↓

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

The drug combination was safe and showed promise in treating advanced tumors.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Tofacitinib is a promising treatment for children with rheumatic diseases.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Familial frontal fibrosing alopecia affects premenopausal women too, and early diagnosis is important, but no proven medication exists yet.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.

Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

PLD is an effective and safer alternative for treating breast cancer.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

As of 1994, treatments for liver cancer had not significantly improved patient survival.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.